In fibromyalgia patients, SAM-e has been
shown to reduce morning stiffness and
fatigue, while reducing pain, and improving
mental outlook.
More well known as a treatment for depression
and osteoarthritis, preliminary research
suggests that SAMe may be helpful for
fibromyalgia symptoms, as well.
SAM-e and Fibromyalgia
Preliminary studies have suggested that SAM-e may
be helpful for those with fibromyalgia. A small double-blind
study evaluated the effect of S-adenosylmethionine
(SAMe, or SAM-e) or placebo in 17 people with fibromyalgia,
11 of whom had depression. The number of tender points
decreased after SAMe but not placebo. Depression,
as assessed by two rating scales, improved after SAMe
but not placebo.
Another double blind trial studied the use of SAM-e
for fibromyalgia and found it to be helpful. In this
trial, 44 people with fibromyalgia took 800 mg of
SAMe or a placebo for 6 weeks. In comparison to the
control group who took a placebo, those taking SAM-e
had improvements in disease activity, such as pain
at rest, fatigue, morning stiffness, and mood. In
other respects, the SAMe group did no better than
the placebo group when it came to reduce tenderness
in their tender points.
Effective Joint Support
SAMe has been used in Europe for two decades for
joint support with positive results. Studies have
shown that the breakdown of SAMe generates sulfate
groups that help maintain joint cartilage. SAM-e also
helps to form proteoglycans, which are used to renew
the matrix of cartilage. Animal studies show that
it increased the production of cartilage-building
cells in joints and may help improve joint lubrication
also. One study proved that SAMe was more effective
than NSAIDs (non-steroidal anti-inflammatory drugs)
when it came to helping with pain associated with
osteoarthritis, with less side effects.
Promotes Mental Well-Being
Studies also show that SAMe helps support a positive
outlook. Although the mechanism by which SAMe promotes
mental well-being is not known, we do know it is able
to cross the blood-brain barrier, where it affects
the production of mood-boosting neurotransmitters.
Supplement Facts
Capsules per Container: 30 Tablets, 400 mg
Serving Size: One (1) Tablet
Servings per Container: 30
Suggested Use: One tablet, one to three times daily.
Take tablets on an empty stomach.
Supplement Facts for 400 mg
Tablet
Serving Size: 1 tablet(s) |
Amount per Serving |
% Daily Value |
SAM-e (S-adenosyl-L-methionine)
from 800 mg of SAMe disulfate tosylate |
|
† |
|
† Daily Value not established.
Other Ingredients: Cellulose, mannitol,
hydroxypropyl methylcellulose pthalate, citric acid,
sodium starch glycolate, glyceryl triacetate, modified
cellulose gum, stearic acid, colloidal silicon dioxide,
titanium dioxide and yellow ochre.
Suitable for vegetarians. Contains no
yeast, dairy, egg, gluten, soy or wheat. Contains
no sugar, salt, preservatives, or artificial flavor
or fragrance.
Warning: If you are pregnant or breastfeeding
consult your physician before using this product.
Sufferers of bipolar disorder shouldn’t use
SAMe unless under medical supervision. Those taking
anti-depressant medications should confer with their
physician before taking SAMe in place of or in addition
to those medications and they should continue to be
monitored. Some caution is advised in those who have
cancer due to the methylating properties of SAMe.
In a small percentage of people this product may cause
nausea which tends to subside with long-term use.
Do not use if either tamper-evident seal is broken
or missing. Keep out of the reach of children.
Manufactured by Source Naturals
The Benefits of SAM-e
You’ve read about it in the media. Europeans
have experienced its health benefits for two decades.
Now consumers in the United States have access to
a nutrient with groundbreaking potential.
SAMe, a natural compound formed in our bodies from
the amino acid methionine, has stirred excitement
due to its wide-ranging health effects. SAMe plays
a critical role in cartilage formation. Clinical studies
have demonstrated that SAMe helps support joint comfort,
function, and mobility in the spine, hips, and knees.
SAMe has also been found to support a positive outlook
due to its affect on the synthesis and activation
of proteins, such as mood-boosting neurotransmitters.
A Multipurpose
Nutrient
SAM-e, or S-adenosyl L-methionine, is formed when
our bodies combine the amino acid L-methionine with
ATP, the primary energy-carrying molecule in our cells.
This nutrient is present in every living cell. Because
SAMe is involved in so many vital processes, it is
important that our bodies produce sufficient amounts.
However, SAMe levels tend to decline with age, and
can also be affected by dietary imbalances.
To produce adequate amounts, we need to consume not
only methionine-containing protein foods, but also
foods rich in vitamins B-6, B-12 and folic acid, which
are needed to ensure the synthesis of SAMe.
Additionally, SAMe is a highly unstable molecule;
therefore, a lot of scientific research was needed
to make it available as a supplement. Source Naturals
has studied the research and offers this vital nutrient
in a form your body can use.
Methylation is the Key
SAMe is known as a “methyl donor.” This
means that it works by giving up a piece of itself
(a methyl group consisting of one carbon and three
hydrogen atoms) to other molecules. This methylation
process affects the synthesis, activation, and metabolism
of various hormones, neurotransmitters, phospholipids,
nucleic acids, proteins, and other biological molecules.
Methylation plays a part in many critical functions,
including the maintenance of cell membranes, the removal
of toxic substances from the body, and the production
of mood-boosting neurotransmitters, such as dopamine
and serotonin.
Effective Joint
Support
SAMe has been used in Europe for two decades for
joint support with positive results. Studies have
shown that the breakdown of SAMe generates sulfate
groups that help maintain joint cartilage. SAMe also
helps to form proteoglycans, which are used to renew
the matrix of cartilage. Animal studies show that
it increased the production of cartilage-building
cells in joints and may help improve joint lubrication
also. One study proved that SAMe was more effective
than NSAIDs (non-steroidal anti-inflammatory drugs)
when it came to helping with pain associated with
osteoarthritis, with less side effects.
Promotes Mental
Well-Being
Studies also show that SAMe helps support a positive
outlook. Although the mechanism by which SAMe promotes
mental well-being is not known, we do know it is able
to cross the blood-brain barrier, where it affects
the production of mood-boosting neurotransmitters.
SAMe and Fibromyalgia
In fibromyalgia patients, SAMe has been shown to reduce morning stiffness and fatigue, while reducing pain, and improving mental outlook.
Preliminary studies have suggested that SAMe may be helpful for those with fibromyalgia. A small double-blind study evaluated the effect of S-adenosylmethionine (SAMe) or placebo in 17 people with fibromyalgia, 11 of whom had depression. The number of tender points decreased after SAMe but not placebo. Depression, as assessed by two rating scales, improved after SAMe but not placebo.
Clinically Researched Potency
Source Naturals SAMe is offered in the clinically
researched potency of 400 mg per suggested daily use
(one tablet). The tablets are enteric coated and blister
packed to prevent breakdown and inactivation of ingredients
References
Berger, R. et al. 1987. “A New Medical Approach....”
The American Journal of Medicine; 83(5A): 84-88.
Carney, MWP et al. 1987. “S-adenosylmethionine....”The
American Journal of Medicine;
83(5A): 104-106.
Konig, B. 1987. “A long-term (two years) clinical
trial of oral S-adenosylmethionine....” The
American Journal of Medicine; 83(5A): 89-94.
Stramentinoli, G. 1987. “Pharmacological aspects
of S-adenosylmethionine.” The American Journal
of Medicine; 83(5A):35-42
Jacobsen S, Danneskiold-Samsoe B, Andersen RB. Oral
S-adenosylmethionine in primary fibromyalgia. Double-blind
clinical evaluation. Scand J Rheumatol. 20.4 (1991):
294-302.
Tavoni A, Vitali C, Bombardieri S, Pasero G. Evaluation
of S-adenosylmethionine in primary fibromyalgia. A
double-blind crossover study. Am J Med. 83.5A (1987):
107-110.
Volkmann H, Norregaard J, Jacobsen S, Danneskiold-Samsoe
B, Knoke G, Nehrdich D. Double-blind, placebo-controlled
cross-over study of intravenous S-adenosyl-L-methionine
in patients with fibromyalgia. Scand J Rheumatol.
26.3 (1997): 206-211.
